Get the Stockscreener App
15.68
3.57%
0.54
Aurinia Pharmaceuticals Inc stock is traded at $15.68, with a volume of 1.28M.
It is up +3.57% in the last 24 hours and up +32.43% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$15.14
Open:
$15.12
24h Volume:
1.28M
Relative Volume:
0.77
Market Cap:
$2.07B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
36.47
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
+2.15%
1M Performance:
+32.43%
6M Performance:
+88.01%
1Y Performance:
+78.79%
1-Day Range:
$14.94
$15.75
1-Week Range:
$14.94
$15.81
52-Week Range:
$6.55
$16.20
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.68 | 2.00B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Is Aurinia Pharmaceuticals Inc. stock positioned for long term growthWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Aurinia Delivers Growth While Balancing Biotech Risks - Finimize
Is Aurinia Pharmaceuticals Inc. stock a good choice for value investorsTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
Will Aurinia Pharmaceuticals Inc. stock deliver consistent dividends2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Will Aurinia Pharmaceuticals Inc. (IKAP) stock return to pre crash levelsEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Will Aurinia Pharmaceuticals Inc. stock see PE expansionJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
Is Aurinia Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 Spike Watch & Low Risk High Win Rate Stock Picks - newser.com
Will Aurinia Pharmaceuticals Inc. (IKAP) stock rise with strong economyTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
How Aurinia Pharmaceuticals Inc. (IKAP) stock correlates with oil marketsJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Chart overlay techniques for tracking Aurinia Pharmaceuticals Inc.2025 Trading Volume Trends & Growth-Oriented Investment Plans - newser.com
What earnings margins imply for Aurinia Pharmaceuticals Inc. (IKAP) stockWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Can Aurinia Pharmaceuticals Inc. (IKAP) stock surprise with quarterly results2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Is Aurinia Pharmaceuticals Inc. stock positioned well for digital economyMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com
Visualizing Aurinia Pharmaceuticals Inc. stock with heatmaps2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):